Rocket Lab USA (RKLB) extended its rally in premarket trading Wednesday after Cathie Wood’s ARK Invest disclosed another purchase of the space company’s shares and Rocket Lab unveiled a new solar cell technology that eliminates a critical material from its design.
The stock climbed more than 3% before the opening bell, adding to a 2.51% gain during Tuesday’s regular session. The advance came even as Nasdaq futures pointed 0.46% lower and S&P 500 futures slipped 0.36%.
The dual catalysts gave investors two company-specific reasons to buy. On the product side, Rocket Lab introduced IMM Apex, a high-efficiency solar cell for space applications that the company says delivers 31.5% beginning-of-life conversion efficiency while cutting mass by 40% compared with earlier models. The design removes germanium substrates, a component that has been standard in multi-junction solar cells for more than three decades and has faced rising costs and supply constraints.
Brad Clevenger, president of Rocket Lab USA, said the cell “delivers exceptional performance while addressing real-world challenges like rising material costs and supply chain constraints.” He added that the product is designed to “more cost-effectively power the most ambitious missions without compromising performance.”
The technology functions as a direct drop-in replacement for existing satellite solar cells, meaning customers can adopt it without significant hardware modifications. Rocket Lab said the cell is available immediately, with manufacturing capacity in the multi-100-kilowatt range. The underlying technology previously powered NASA’s Ingenuity Mars Helicopter and has operated in orbit for more than a decade. Rocket Lab’s solar products currently support more than 1,100 satellites, including the James Webb Space Telescope and NASA’s Artemis missions.
On the ownership side, the ARK Space Exploration & Innovation ETF (ARKX) bought 2,341 Rocket Lab shares on Tuesday, a transaction worth roughly $154,000 based on the closing price. That follows a substantially larger buying spree: ARK acquired 705,102 shares across three exchange-traded funds over two trading days earlier this month, worth about $44.4 million. The purchases were made through ARKX, the ARK Innovation ETF (ARKK), and the ARK Autonomous Technology & Robotics ETF (ARKQ).
Rocket Lab now carries a 5.70% weighting in ARKX, along with a 4.07% position in ARKQ and a 4.04% stake in the Defiance Space and Connective Tech ETF (UFOX). Because the stock holds sizable weightings in these funds, ETF inflows and outflows can contribute to meaningful buying or selling pressure.
Operational Momentum
Beyond the immediate catalysts, Rocket Lab has been building operational credibility. The company completed its 94th Electron mission last week, deploying a StriX Earth-imaging satellite for Japanese radar company Synspective. It was Rocket Lab’s 15th launch of 2026 and its 11th dedicated mission for Synspective, with a 100% success rate across those flights. Another 16 Synspective missions are booked through 2030.
Rocket Lab also passed the preliminary design review for 18 satellites it is building for the U.S. Space Development Agency’s Tracking Layer Tranche 3 constellation, a milestone the company called a “big step forward” toward delivering missile-warning and defense capabilities for the United States and its allies.
Financially, the company reported $234.1 million in second-quarter revenue, a 62% year-over-year expansion. Its contract backlog reached a record $2.36 billion. Rocket Lab’s market capitalization stands at approximately $39.4 billion.
Wall Street’s View
Analysts remain broadly constructive on the stock. Rocket Lab carries a Strong Buy consensus rating, with 13 Buy recommendations and four Hold ratings issued over the past three months. The average price target sits at $108.88, implying roughly 65% upside from current levels.
Recent analyst actions include Bank of America Securities maintaining a Buy rating while trimming its price target to $110 on Aug. 31. Citizens held a Market Outperform rating with a $130 forecast on Aug. 11, while Cantor Fitzgerald maintained an Overweight rating and raised its target to $122 the same day.
Technical Picture
Despite the recent bounce, Rocket Lab remains below its major moving averages. The stock trades 4.9% below its 20-day simple moving average and 9.4% below its 50-day SMA. It sits 25.1% below the 100-day SMA and 15.1% below the 200-day SMA. The 20-day SMA remains below the 50-day SMA, and the 50-day crossed below the 200-day in August, forming a “death cross” that points to pressure on the longer-term trend.
Momentum indicators also suggest caution. The MACD sits below its signal line with a negative histogram, indicating buying momentum has not fully recovered. Rocket Lab faces resistance near $78.50, with support around $58.50.
The stock has gained roughly 38% over the trailing twelve months but remains well below its 52-week high of $151, reflecting the extent of the pullback since May. The 52-week range spans from $37.57 to $151, and the relative strength index reading sits at 40.94.
On Stocktwits, retail sentiment for RKLB slipped to “bearish” from “neutral” levels a week ago, even as 24-hour message volumes jumped 369%. One bullish user wrote, “$RKLB bought 500 shares of this back in 2024 when it was at $9 and sold in the $20’s and I regretted it. I repurchased 1k shares last week at $59 and ain’t selling till we are at $150.”
Once added, BigGo Finance appears first in Google Search Top Stories, so you get the broadest, most up-to-the-minute, and most comprehensive global financial news first.
The news and data on this website are for reference only and do not constitute investment advice or an offer to buy or sell. Information is sourced from exchanges and public sources, and may be delayed, interrupted, or updated. While we strive for accuracy, we do not guarantee timeliness, correctness, or completeness. Content may include external links for which we are not responsible. By using this site, you agree that we and our partners are not liable for any losses. Investment carries full responsibility; please carefully assess risks and consult professionals. If there are errors in the content, please contact us for correction.

source